Alastair McEwan, a former executive with Inveresk Research Group, is the new chief financial officer of Cornerstone BioPharma.
McEwan also joins Cornerstone’s board of directors.
Cornerstone is a developer of anti-infective and respiratory treatments as well as research into the central nervous system.
McEwan was president of Inveresk’s global clinical division. Inveresk was acquired by Charles River Laboratories last year.
Other board members include Craig Collard, founder and chief executive officer of Cornerstone; Jim Baker, president and CEO of Atlantic Search Group Inc.; and Philip Pesin, founding partner of the California based law firm, Pesin & Blatz.
McEwan moved to the United States in 2001 following Inveresk’s acquisition of the ClinTrials Research Group. He holds a Bachelors of Commerce degree from the University of Edinburgh, and is a Chartered Accountant and a Member of the Institute of Directors.
Cornerstone: www.cornerstonebiopharma.com
